TY - JOUR T1 - Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with IPF JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00082-2022 SP - 00082-2022 AU - Theodoros Karampitsakos AU - Ourania Papaioannou AU - Ilias Dimeas AU - Panagiota Tsiri AU - Vasilina Sotiropoulou AU - Ioannis Tomos AU - Ilias C Papanikolaou AU - Matthaios Katsaras AU - Paraskevi Kirgou AU - Zoe Daniil AU - Konstantinos I Gourgoulianis AU - Fotios Sampsonas AU - Effrosyni Manali AU - Spyridon Papiris AU - Demosthenes Bouros AU - Argyris Tzouvelekis Y1 - 2022/01/01 UR - http://openres.ersjournals.com/content/early/2022/03/17/23120541.00082-2022.abstract N2 - The emergence and spread of 2019 coronavirus disease (COVID-19) are causing a growing global public health crisis. Despite advances in treatment, vaccination remains the best way to contain the pandemic [1]. Vaccines are currently available by means of conditional marketing approval, full approval and emergency use authorization pathways [2]. Evidence suggest that immunocompromised individuals including solid organ transplants recipients and patients under immunosuppressive treatment may have increased mortality from SARS-CoV-2 infection despite double dose messenger RNA (mRNA) vaccine regimens [3]. This is partially attributed to blunted immune responses to vaccination since only 38–54% of kidney and liver transplant recipients developed detectable SARS-CoV-2 antibodies following the second dose of mRNA vaccines [3, 4].FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Demosthenes Bouros reports receiving grants or contracts from Roche and Boehringer Ingelheim, outside the submitted work. Honoraria received from Roche and Boehringer Ingelheim outside the submitted work.Spyridon Papiris reports receiving grants or contracts from Roche and Boehringer Ingelheim, outside the submitted work. Honoraria received from Roche and Boehringer Ingelheim outside the submitted work.Effrosyni Manali reports receiving grants or contracts from Roche and Boehringer Ingelheim, outside the submitted work. Honoraria received from Roche and Boehringer Ingelheim outside the submitted work.Zoe Daniil reports receiving grants or contracts from Roche and Boehringer Ingelheim, outside the submitted work. Honoraria received from Roche and Boehringer Ingelheim outside the submitted work.Argyris Tzouvelekis reports receiving grants or contracts from Roche and Boehringer Ingelheim, outside the submitted work. Honoraria received from Roche and Boehringer Ingelheim outside the submitted work.The remaining authors have nothing to disclose. ER -